Literature DB >> 1724398

Current concepts in the treatment of genitourinary tract disorders in the older individual.

A Atala1, M Amin.   

Abstract

Genitourinary problems, including neurogenic dysfunction, impotence, prostatism, urinary tract infections, and prostate cancer, are common in the elderly, and most of the symptoms can be alleviated through pharmacological management. Patients with neurogenic dysfunction who present with symptoms such as incontinence and urinary retention can be appropriately managed with bladder and sphincter relaxants or stimulants. Anticholinergic agents in the form of oxybutynin, flavoxate, and propantheline are effective bladder relaxants, and phenoxybenzamine, prazosin, and terazosin are commonly used as sphincter relaxants. Bethanechol chloride is the agent most commonly used to stimulate bladder contraction, but physicians should be careful when prescribing it for elderly patients with cardiovascular problems. Organic and psychogenic causes of impotence usually overlap, and oral agents have limited use in the treatment process. The use of yohimbine has increased recently, but its value and rate of success remains questionable. Testosterone is being used widely to treat impotence, but it is only helpful to patients with hypogonadism and should be used with discretion in the elderly, who have a high incidence of prostate cancer. Vasoactive intracavernous pharmacotherapy, on the other hand, is a recently discovered alternative to testosterone with promising results. Although the treatment of choice for benign prostatic hypertrophy is surgery, there have been important pharmacological advances in treating this disorder. alpha-Adrenergic antagonists and anti-androgenic agents have been found to relieve the symptoms of prostatic enlargement. The use of chemotherapeutic and antibiotic agents to treat and suppress acute and chronic urinary tract infections is reviewed; these are second only to pulmonary infections as the most frequent cause of febrile episodes in patients over the age of 65. Lower urinary tract infections can be treated with almost any antibacterial agent. Upper urinary tract infections require full genitourinary evaluation and appropriate antibiotics should be used according to the urine culture sensitivity studies. With the advent of new hormonal agents, more choices are now available for the management of prostate cancer, which is the second most common malignancy in men. Diethylstilbestrol (stilboestrol), an oral estrogen, remains a commonly used agent to achieve castrate levels of androgens in advanced prostatic carcinoma. Agonist analogues, such as goserelin and leuprorelin, of gonadotrophin-releasing hormone (GnRH) [luteinising hormone-releasing hormone (LHRH); or gonadorelin] achieve the same results as diethylstilbestrol but without the cardiovascular side effects. Antiandrogens are also being used in combination with GnRH agonists to produce complete androgen blockage, with mixed results.

Entities:  

Mesh:

Year:  1991        PMID: 1724398     DOI: 10.2165/00002512-199101030-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  75 in total

1.  Biopharmaceutic influences on the anticholinergic effects of propantheline.

Authors:  M Gibaldi; B Grundhofer
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  I. The Results of Double Castration in Hypertrophy of the Prostate.

Authors:  J W White
Journal:  Ann Surg       Date:  1895-07       Impact factor: 12.969

3.  Functional evaluation of penile veins by cavernosography in papaverine-induced erection.

Authors:  T F Lue; H Hricak; R A Schmidt; E A Tanagho
Journal:  J Urol       Date:  1986-03       Impact factor: 7.450

4.  Yohimbine: time for resurrection?

Authors: 
Journal:  Lancet       Date:  1986-11-22       Impact factor: 79.321

Review 5.  The mechanism of the irreversible antimicrobial effects of penicillins: how the beta-lactam antibiotics kill and lyse bacteria.

Authors:  A Tomasz
Journal:  Annu Rev Microbiol       Date:  1979       Impact factor: 15.500

6.  Alpha-adrenergic blockers in prostatism.

Authors:  P F Boreham; P Braithwaite; P Milewski; H Pearson
Journal:  Br J Surg       Date:  1977-10       Impact factor: 6.939

Review 7.  Self-administration in the pharmacological treatment of impotence.

Authors:  F Bénard; T F Lue
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

8.  Endocrine changes after diethylstilbestrol therapy. Effects on prostatic neoplasm and pituitary-gonadal axis.

Authors:  G R Prout; B Kliman; J J Daly; R A MacLaughlin; P P Griffin; H H Young
Journal:  Urology       Date:  1976-02       Impact factor: 2.649

Review 9.  Nafarelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical potential in sex hormone-related conditions.

Authors:  P Chrisp; K L Goa
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

10.  Infections among patients in nursing homes: policies, prevalence, problems.

Authors:  R A Garibaldi; S Brodine; S Matsumiya
Journal:  N Engl J Med       Date:  1981-09-24       Impact factor: 91.245

View more
  3 in total

Review 1.  Comparison of the cost-effectiveness of various therapies for common prostatic disorders.

Authors:  E A Amin; M Amin
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

Review 2.  Leuprorelin. A review of its pharmacology and therapeutic use in prostatic disorders.

Authors:  P Chrisp; E M Sorkin
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

Review 3.  Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.

Authors:  Y E Yarker; K L Goa; A Fitton
Journal:  Drugs Aging       Date:  1995-03       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.